Noramco, headquartered in Wilmington, Delaware, is a global leader in the production of controlled substances for the pharmaceutical industry, for medicines used to treat attention deficit hyperactivity disorder, pain, addiction, and for abuse-deterrent formulations. We realize our success through a keen focus on commercial and operational excellence as well as continuing strategic growth. Our global footprint includes Athens, GA, Wilmington, DE and Neuhausen, Switzerland. 

Specialists in controlled substance development and manufacturing, Noramco is a partner to the pharmaceutical industry:

– Focusing on  high-purity controlled substances
– Leveraging intellectual property to devise the most efficient routes to APIs
– Providing analytical data, chemical and physical properties, stability studies and regulatory assistance
– Formulation friendly particle size grades and extended technical packages
– Delivering DEA-compliant security and production capacity, from kilos to multi-ton supply
– Supporting world-class supply security of controlled-substances, from schedule I to schedule III

Chemicals

Manufacturing

Pharmaceutical

Noramco™

Alan Majewski

Anthony Ambrosini

Philipp Baer

Mathew Minardi

Dave Tennett

Scott Warner

Bill Grubb

The Research and Development Team at Noramco™ is dedicated to innovating and optimizing the development of high-purity controlled substances for the pharmaceutical industry. This team conducts rigorous research, designs efficient processes for active pharmaceutical ingredients (APIs), and provides critical analytical data and stability studies to ensure regulatory compliance. By leveraging their expertise, they support the creation of safe and effective medications while maintaining stringent security and supply chain standards.

Research and Development Team

Engineering and Technical Specialists

Leadership Team

Research and Development Team

About

Team members

Other teams at Noramco™

Engineering and Technical Specialists

Leadership Team